Microbot Medical (NASDAQ:MBOT) Upgraded at Wall Street Zen

Key Points

• Microbot Medical was upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment towards the company.
• HC Wainwright raised its price objective for Microbot Medical from $9.00 to $12.00 while assigning a "buy" rating, amidst conflicting opinions from other analysts.
• The company reported a quarterly loss of ($0.10) earnings per share, missing expectations, and analysts predict an average annual EPS of -0.71 for Microbot Medical.

Microbot Medical (NASDAQ:MBOT - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.

Other research analysts have also issued reports about the company. HC Wainwright upped their price objective on Microbot Medical from $9.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, September 11th. Zacks Research downgraded shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 21st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Microbot Medical in a research note on Saturday, September 27th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Microbot Medical has an average rating of "Hold" and an average price target of $12.00.

Microbot Medical Stock Performance

MBOT traded down $0.10 on Friday, reaching $3.07. The company had a trading volume of 3,466,703 shares, compared to its average volume of 7,348,642. The stock has a market cap of $162.07 million, a P/E ratio of -5.29 and a beta of 1.25. Microbot Medical has a fifty-two week low of $0.88 and a fifty-two week high of $4.67. The company's fifty day moving average is $3.33 and its 200 day moving average is $2.68.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.02). On average, sell-side analysts expect that Microbot Medical will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Microbot Medical by 24.7% during the second quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company's stock worth $996,000 after purchasing an additional 78,121 shares during the last quarter. DNB Asset Management AS raised its holdings in shares of Microbot Medical by 67.9% during the 2nd quarter. DNB Asset Management AS now owns 192,786 shares of the biotechnology company's stock worth $486,000 after buying an additional 77,965 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical during the 1st quarter worth $57,000. Virtu Financial LLC acquired a new stake in Microbot Medical in the first quarter valued at about $42,000. Finally, Lazari Capital Management Inc. acquired a new stake in Microbot Medical in the second quarter valued at about $54,000. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.